Description:
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance
Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose
Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Title
- Brief Title: Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
- Official Title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Clinical Trial IDs
- ORG STUDY ID:
D081FC00001
- SECONDARY ID:
2014-001589-85
- NCT ID:
NCT02184195
Conditions
- Germline BRCA1/2 Mutations and
- Metastatic Adenocarcinoma of the Pancreas
Interventions
| Drug | Synonyms | Arms |
|---|
| Olaparib | | Olaparib |
| Olaparib | | Olaparib |
| Placebo | | Placebo |
| Placebo | | Placebo |
Purpose
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance
Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose
Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Detailed Description
Approximately 145 patients will be randomised using an Interactive Voice Response System
/Interactive Web Response System (IVR/IWR system) in a 3:2 ratio (Olaparib:placebo) to the
treatments as specified below:
- Olaparib tablets p.o. 300 mg twice daily
- Matching placebo tablets p.o. twice daily Eligible patients will be those patients with
pancreas cancer previously treated for metastatic disease who have not progressed
following completion of at least 16 weeks (can be more) of first line platinum-based
chemotherapy. All patients must have a known deleterious or suspected deleterious
germline BRCA mutation to be randomised; this may have been determined prior to
enrolment into the study or may be assessed as part of the enrolment procedure for the
study (via centrally provided MyriadIntegrated BRAC.
Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose
is the day of the last infusion) and treatment started as soon as possible but no less than 4
and no more than 8 weeks of the last chemotherapy dose. At the time of starting protocol
treatment, all previous chemotherapy treatment should be discontinued.
Following randomisation, patients will attend clinic visits weekly for the first 4 weeks of
treatment (Days 8, 15, 22 and 29). Patients will then attend clinic visits every 4 weeks
whilst on study treatment. Patients should continue to receive study treatment until
objective radiological disease progression as per RECIST as assessed by the investigator and
as long as in the investigator's opinion they are benefiting from treatment and they do not
meet any other discontinuation criteria.
Once a patient has progressed the patient will be followed for second progression (PFS2)
every 8 weeks and then survival until the final analysis.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Olaparib | Experimental | Olaparib tablets po. 300 mg twice daily | |
| Placebo | Placebo Comparator | Placebo tablets twice daily | |
Eligibility Criteria
Key Inclusion Criteria
- Histologically or cytologically confirmed pancreas adenocarcinoma receiving initial
chemotherapy for metastatic disease and without evidence of disease progression on
treatment
- Patients with measurable disease and/or non-measurable or no evidence of disease
assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in
this study.
- Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or
suspected deleterious
- Patients are on treatment with a first line platinum-based (cisplatin, carboplatin or
oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16
weeks of continuous platinum treatment and have no evidence of progression based on
investigator's opinion.
- Patients who have received platinum as potentially curative treatment for a prior
cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for pancreas cancer
are eligible provided at least 12 months have elapsed between the last dose of
platinum-based treatment and initiation of the platinum-based chemotherapy for
metastatic pancreas cancer.
Major Exclusion Criteria:
- gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg,
"Variants of uncertain clinical significance" or "Variant of unknown significance" or
"Variant, favour polymorphism" or "benign polymorphism" etc.)
- Progression of tumour between start of first line platinum based chemotherapy for
metastatic pancreas cancer and randomisation.
- Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle
1 Day 1 is not permitted.
- Exposure to an investigational product within 30 days or 5 half lives (whichever is
longer) prior to randomisation
- Any previous treatment with a PARP inhibitor, including Olaparib
| Maximum Eligible Age: | 130 Years |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1) |
| Time Frame: | Up to 4 years |
| Safety Issue: | |
| Description: | To determine the efficacy of olaparib maintenance monotherapy compared to placebo by PFS. The PFS was defined as the time from randomisation until the date of objective radiological disease progression according to modified RECIST v1.1 or death (by any cause in the absence of disease progression) regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to disease progression. |
Secondary Outcome Measures
| Measure: | Overall Survival (OS) |
| Time Frame: | Upto 4 years |
| Safety Issue: | |
| Description: | To determine the efficacy by assessment of OS of olaparib maintenance monotherapy compared to placebo. The OS was defined as the time from the date of randomization until death due to any cause. |
| Measure: | Time From Randomisation to Second Progression (PFS2) |
| Time Frame: | Up to 4 years |
| Safety Issue: | |
| Description: | To determine efficacy by assessment of PFS2 of olaparib maintenance monotherapy compared to placebo. The PFS2 was defined as the time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death. |
| Measure: | Time From Randomisation to Second Subsequent Therapy or Death (TSST) |
| Time Frame: | Up to 4 years |
| Safety Issue: | |
| Description: | To determine the efficacy by assessment of TSST of olaparib maintenance monotherapy compared to placebo. The TSST was defined as time to second subsequent therapy or death. |
| Measure: | Time From Randomisation to First Subsequent Therapy or Death (TFST) |
| Time Frame: | Up to 4 years |
| Safety Issue: | |
| Description: | To determine the efficacy by assessment of TFST of olaparib maintenance monotherapy compared to placebo. The TFST was defined as time to first subsequent therapy or death. |
| Measure: | Time From Randomisation to Study Treatment Discontinuation or Death (TDT) |
| Time Frame: | Up to 4 years |
| Safety Issue: | |
| Description: | To determine the efficacy by assessment of TDT compared to placebo. compared to placebo. The TDT was defined as time to study treatment discontinuation or death. |
| Measure: | Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1 |
| Time Frame: | Up to 4 years |
| Safety Issue: | |
| Description: | To determine efficacy by assessment of objective response rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo. The ORR is defined as the number of with a BoR of CR and PR according to the BICR data divided by the number of patients in the treatment group with measurable disease at baseline. |
| Measure: | Disease Control Rate (DCR) by BICR Using Modified RECIST 1.1 |
| Time Frame: | At 16 weeks |
| Safety Issue: | |
| Description: | Efficacy by assessment of disease control rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo. |
| Measure: | Adjusted Mean Change From Baseline up to 6 Months in Global Quality of Life (QoL) Score From the EORTC-QLQ-C30 Questionnaire |
| Time Frame: | From baseline up to 6 months |
| Safety Issue: | |
| Description: | To assess the effect of olaparib on health-related quality of life (QoL) as measured by the EORTC-QLQ-C30 global QoL scale. The EORTC-QLQ-C30 is defined as EORTC QLQ-C30: a questionnaire (30 questions) used to evaluate disease symptoms, functional impacts (eg, physical functioning), and HRQoL and to characterize clinical benefit from the patient perspective. The HRQoL score ranges from 0 to 100.
A higher score indicates better QoL. A score change of 10 points was pre-defined as clinically meaningful.
bd twice daily. |
| Measure: | Number of Participants With Adverse Events (AEs) |
| Time Frame: | Up to 4 years |
| Safety Issue: | |
| Description: | To assess the safety and tolerability of olaparib maintenance monotherapy. SAE: serious adverse events CTCAE: Common Terminology Criteria for Adverse Events |
Details
| Phase: | Phase 3 |
| Primary Purpose: | Interventional |
| Overall Status: | Active, not recruiting |
| Lead Sponsor: | AstraZeneca |
Trial Keywords
- BRCA, metastatic adenocarcinoma pancreas, maintenance olaparib monotherapy, first line platinum chemotherapy, pancreatic cancer, PARP inhibitor
Last Updated
June 18, 2021
